Retatrutide: The Next Generation
of GLP-1 Weight Loss
Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist from Eli Lilly. It is not FDA-approved and is not for sale. Lilly plans a Q1 2027 BLA filing; an approval decision has not been announced.
Weight-change figure is the Lilly efficacy estimand (21 May 2026). Treatment-regimen results are lower. BLA plan: Lilly, 23 Jul 2026. Filing is not approval.
Get an email when Lilly files — or if FDA acts
This waitlist is run by NextGenGLP1. It is not an Eli Lilly program, not a consumer queue at Lilly, and not exclusive early-access pricing.
How Retatrutide Works
Retatrutide is a triple agonist: it activates GIP, GLP-1, and glucagon receptors. It has no brand name. It is not a published head-to-head versus Zepbound (TRIUMPH-5, NCT06662383, has not reported).
Triple-Receptor Action
Targets GLP-1, GIP, and glucagon receptors in a single investigational molecule. Not FDA-approved.
Phase 3, labeled estimand
TRIUMPH-1 (12 mg) reported −28.3% mean weight change at 80 weeks on Lilly’s efficacy estimand (21 May 2026). That is not a Zepbound comparison.
Once-Weekly Injection
Studied as a once-weekly subcutaneous injection in Lilly’s TRIUMPH program. Not an approved product you can buy.
Also in other trials
Phase 3 programs include type 2 diabetes, knee osteoarthritis pain, and other obesity complications. Earlier fatty-liver figures are not Phase 3 TRIUMPH results.
Can't wait for retatrutide? Talk with a clinician about GLP-1 care available today.
Retatrutide is not for sale. These telehealth partners offer clinician consults for other GLP-1 options available today. They do not sell retatrutide.
Compounded GLP-1 + GIP through a telehealth consult. Not FDA-approved branded tirzepatide (not Zepbound/Mounjaro). Not retatrutide. Medical consultation required.
Semaglutide and tirzepatide with licensed physicians. Includes medical consultation.
NextGenGLP1 may earn a commission at no cost to you. Compounded medication is not FDA-approved. A prescription is issued only after a medical consultation. Pricing on partner sites can change.
Latest Retatrutide Updates
FDA Approval Status: Not Approved
As of 24 Aug 2026, retatrutide is not FDA-approved. Lilly plans a Q1 2027 BLA. Phase 3 results and what to do now.
Retatrutide vs Tirzepatide
Different drugs. TRIUMPH-5 (NCT06662383), the head-to-head versus tirzepatide, has not reported.
Safety Guide: Side Effects Explained
GI effects plus dysesthesia in Phase 3. This is not a complete safety list — read the full guide.
Stay updated on retatrutide’s FDA path
We’ll email you if Lilly files a BLA or if FDA acts. This list is not a Lilly waitlist.